StockNews.com Begins Coverage on Minerva Neurosciences (NASDAQ:NERV)

Research analysts at StockNews.com initiated coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research report issued on Sunday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating and issued a $5.00 price target on shares of Minerva Neurosciences in a report on Wednesday, February 26th.

Minerva Neurosciences Price Performance

NASDAQ NERV opened at $1.76 on Friday. Minerva Neurosciences has a fifty-two week low of $1.15 and a fifty-two week high of $3.69. The stock’s 50-day moving average is $1.63 and its two-hundred day moving average is $2.04. The firm has a market cap of $12.31 million, a P/E ratio of -4.00 and a beta of -0.09.

Minerva Neurosciences (NASDAQ:NERV) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($1.05) by $0.49. On average, equities analysts expect that Minerva Neurosciences will post -0.3 EPS for the current year.

Institutional Trading of Minerva Neurosciences

Several institutional investors have recently made changes to their positions in NERV. Apella Capital LLC bought a new position in Minerva Neurosciences during the first quarter worth about $35,000. Citadel Advisors LLC raised its stake in Minerva Neurosciences by 49.5% during the fourth quarter. Citadel Advisors LLC now owns 25,764 shares of the biopharmaceutical company’s stock worth $57,000 after acquiring an additional 8,525 shares in the last quarter. Finally, Northern Trust Corp raised its stake in Minerva Neurosciences by 60.0% during the fourth quarter. Northern Trust Corp now owns 36,878 shares of the biopharmaceutical company’s stock worth $82,000 after acquiring an additional 13,829 shares in the last quarter. 34.56% of the stock is currently owned by institutional investors and hedge funds.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.